FI3445351T3 - Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen - Google Patents
Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen Download PDFInfo
- Publication number
- FI3445351T3 FI3445351T3 FIEP17719692.0T FI17719692T FI3445351T3 FI 3445351 T3 FI3445351 T3 FI 3445351T3 FI 17719692 T FI17719692 T FI 17719692T FI 3445351 T3 FI3445351 T3 FI 3445351T3
- Authority
- FI
- Finland
- Prior art keywords
- acetylleucine
- pharmaceutically acceptable
- acceptable salt
- method comprises
- comprises administering
- Prior art date
Links
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title claims 16
- 229960000669 acetylleucine Drugs 0.000 title claims 16
- 150000003839 salts Chemical class 0.000 title claims 10
- 238000000034 method Methods 0.000 claims 14
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3445351T3 true FI3445351T3 (fi) | 2024-11-18 |
Family
ID=58633040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17719692.0T FI3445351T3 (fi) | 2016-04-19 | 2017-04-19 | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (enExample) |
| EP (2) | EP3445351B1 (enExample) |
| JP (3) | JP7387264B2 (enExample) |
| KR (4) | KR102632670B1 (enExample) |
| CN (2) | CN109069463B (enExample) |
| AU (2) | AU2017252507B2 (enExample) |
| BR (1) | BR112018071547A2 (enExample) |
| CA (2) | CA3309723A1 (enExample) |
| DK (1) | DK3445351T3 (enExample) |
| ES (1) | ES2994242T3 (enExample) |
| FI (1) | FI3445351T3 (enExample) |
| HR (1) | HRP20241552T1 (enExample) |
| HU (1) | HUE069219T2 (enExample) |
| IL (3) | IL293266B2 (enExample) |
| LT (1) | LT3445351T (enExample) |
| MD (1) | MD3445351T2 (enExample) |
| MX (2) | MX388461B (enExample) |
| PL (1) | PL3445351T3 (enExample) |
| PT (1) | PT3445351T (enExample) |
| RS (1) | RS66142B1 (enExample) |
| RU (1) | RU2745912C2 (enExample) |
| SG (2) | SG10202106190RA (enExample) |
| SI (1) | SI3445351T1 (enExample) |
| SM (1) | SMT202400459T1 (enExample) |
| WO (1) | WO2017182802A1 (enExample) |
| ZA (1) | ZA201806849B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3445351T (pt) | 2016-04-19 | 2024-11-14 | Intrabio Ltd | Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade |
| TN2019000033A1 (fr) | 2016-08-11 | 2020-07-15 | Intrabio Ltd | Agents thérapeutiques pour maladies neurodégénératives |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| CN120157593A (zh) | 2018-12-06 | 2025-06-17 | 内在生物技术有限公司 | 乙酰基-亮氨酸的氘代类似物 |
| CN119097618A (zh) * | 2019-03-02 | 2024-12-10 | 内在生物技术有限公司 | 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 |
| MD3989962T2 (ro) * | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| WO2021144720A1 (en) | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| WO2025019570A1 (en) | 2023-07-18 | 2025-01-23 | Sytheon Ltd. | Novel amino acid based salts, compositions and methods for treating skin and rejuvenating skin and extending longevity |
| WO2025166100A1 (en) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| AU2007352854A1 (en) * | 2007-05-08 | 2008-11-13 | Northern Innovations And Formulations Corp. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| WO2011025518A1 (en) * | 2009-08-27 | 2011-03-03 | Albert Einstein College Of Medicine Of Yeshiva University | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| PT3445351T (pt) * | 2016-04-19 | 2024-11-14 | Intrabio Ltd | Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade |
| EP3697406A1 (en) * | 2017-10-18 | 2020-08-26 | IntraBio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 CA CA3309723A patent/CA3309723A1/en active Pending
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MY179696A (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| PH12017500746A1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| HK1209341A1 (zh) | 與治療柏金遜症相關之運動與動作障礙副作用之治療 | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| EA201790991A1 (ru) | Способ лечения с использованием пегилированного интерферона | |
| MX2020005438A (es) | Formas de dosificacion de sulfato de morfina disuasivas del abuso. | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| HK1246687A1 (zh) | 治疗与帕金逊症治疗相关的运动失调及其副作用的方法 | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| RU2015122823A (ru) | Способ лечения печёночной энцефалопатии у больных циррозом печени | |
| AR103764A1 (es) | Pridopidina como mejoradora de la función cognitiva y en el tratamiento de la enfermedad de alzheimer | |
| UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті | |
| IN2014MU01185A (enExample) | ||
| IN2014MU01184A (enExample) | ||
| IN2013MU01155A (enExample) | ||
| IN2014DE00822A (enExample) |